



# Association of 2 Lysyl Oxidase Gene Single Nucleotide Polymorphisms with Keratoconus

## A Nationwide Registration Study

Sana Niazi, MD,<sup>1</sup> Majid Moshirfar, MD,<sup>2</sup> Fatemeh Alizadeh, PhD,<sup>3</sup> Farideh Doroodgar, MD,<sup>4,5</sup> Alireza Baradaran-Rafii, MD,<sup>6,7</sup> Oliver Filutowski, MD,<sup>7</sup> Feizollah Niazi, MD,<sup>8</sup> Renato Ambrósio, Jr., MD, PhD<sup>9,10,11,12,13</sup>

**Purpose:** Keratoconus (KC) is the most common primary ectatic corneal disease, characterized by progressive thinning of the cornea, affecting its shape and structure and leading to visual loss. Lysyl oxidase is an important component of the extracellular matrix and contributes to the homeostasis of corneal stromal extracellular matrix via enzymatic reaction. This nationwide registration study aims to examine the association of KC with 2 known single nucleotide polymorphisms, rs2956540 and rs10519694, in a population of Iranian descent.

**Design:** Case-control.

**Participants:** One hundred seventy-eight subjects with KC and 180 clinically healthy subjects participated in the study.

**Methods:** Genomic DNA was extracted from peripheral blood samples, and their genotypes were determined using tetra-primer amplification refractory mutation system–polymerase chain reaction.

**Main Outcome Measures:** Allele frequency for rs2956540 and rs10519694.

**Results:** Genotype frequency was significantly different between cases and controls for rs2956540 ( $P$  value = 0.019). The rs2956540 C allele carriers were significantly more frequent among KC cases than healthy controls ( $P$  value<sub>chi-square</sub> = 0.015,  $P$  value<sub>Fisher exact</sub> = 0.017). There was a significant difference in genotype frequency between groups for rs10519694 ( $P$  value = 0.001). T allele carriers were significantly more frequent among KC patients ( $P$  value<sub>chi-square</sub> = 0.002,  $P$  value<sub>Fisher exact</sub> = 0.001). Sex stratification revealed no significant differences in genotype frequency between males and females in cases and controls. Fitting the general linear model showed that rs10519694 could be considered a predictor for the development of KC ( $P$  value = 0.001); however, this was not observed for rs2956540 ( $P$  value = 0.323).

**Conclusions:** rs2956540 and rs10519694 are associated with KC in a population of Iranian descent. rs10519694 could potentially be used for KC risk prediction. *Ophthalmology Science* 2023;3:100247 © 2022 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



Supplemental material available at [www.ophthalmologyscience.org](http://www.ophthalmologyscience.org).

Keratoconus (KC), or conical cornea, is characterized by bilateral, progressive, noninflammatory thinning and protrusion of the cornea, which usually leads to visual impairment from myopia and irregular astigmatism.<sup>1</sup> KC is the most common corneal ectatic disorder<sup>2</sup> and one of the most common reasons for corneal transplantation, especially in younger patients.<sup>3-5</sup> Its estimated prevalence is 0.17 to 47.90 per 1000 in different populations.<sup>6-8</sup> Both genders are equally affected, and the disease is more prevalent among Asian individuals than White individuals.<sup>8,9</sup>

Keratoconus is a multifactorial disease with a single etiology remaining unknown. Family-based and twin studies have demonstrated that both genetic and environmental factors impact pathogenesis.<sup>10-12</sup>

Histochemical analysis shows disturbances in the homeostasis of the extracellular matrix (ECM) of the keratoconic cornea.<sup>13,14</sup> Lysyl oxidase (*LOX*),<sup>15</sup> metalloproteinase 9,<sup>16,17</sup> tissue inhibitor of metalloproteinase 1 and 2,<sup>16,17</sup> transforming growth factor beta-induced gene (*TGFBI*),<sup>16,18,19</sup> glycoprotein fibronectin (*FN1*),<sup>16</sup> integrin,<sup>16</sup> and thrombospondin 1<sup>16,20</sup> are some examples of ECM-related genes involved in the development of KC.

*LOX* is a copper-dependent enzyme encoded by the *LOX* gene (location: 5q23.2) that plays an important role in maintaining the ECM by forming elastin and collagen cross-links using oxidative deamination catalysis of lysine and hydroxylysine residues.<sup>21</sup> Connections between the *LOX* chromosomal location in familial KC and altered *LOX*

Table 1. Pentacam Criteria for Risk of Keratectasia

Criteria	Normal	Suspect	Abnormal
Pentacam			
K max (D)	< 47.2	47.2–49	> 49
Against the rule astigmatism (D)	< 1	1–2	> 2
Corneal astigmatism (D)	< 6	6–7	> 7
Thinnest point ( $\mu\text{m}$ )	> 500	470–500	< 470
Difference between pachy apex and thinnest location ( $\mu\text{m}$ )	< 10	10–20	> 20
Difference in central thickness between 2 eyes ( $\mu\text{m}$ )	< 10	10–30	> 30
Displacement of the thinnest point from the center (mm)	< 0.5	0.5–1	> 1
Skewed steepest radial axis (SRAX) (degrees)	< 10	10–20	> 21
IS value (inferior–superior difference at the 3 mm) (D)	< 1.4	1.4–1.9	> 1.9
IS value (inferior–superior difference at the 5 mm) (D)	< 1.4	1.4–2.5	> 2.5
Anterior elevation ( $\mu\text{m}$ )	< 10	10–12	> 12
Posterior elevation ( $\mu\text{m}$ )	< 15	15–17	> 17

D= diopter; IS value = the inferior-superior value.

activity in individuals with KC support the promising role of *LOX* in the incidence of KC.<sup>22–24</sup> A case–control genome-wide association study in White American individuals revealed that the association of KC with single nucleotide polymorphisms (SNPs) lies within *LOX*.<sup>15</sup>

Several studies have already highlighted the role of *LOX* variants, especially SNPs, in the risk of KC.<sup>15,23,25–27</sup> A study in an Iranian population demonstrated that rs1800449 is significantly associated with KC and increasing KC risk, whereas a similar effect was not observed in rs2288393.<sup>21</sup> Another study revealed that both rs1800449 and rs2956540 are significantly associated with KC,<sup>15</sup> as did a separate study of European descendants examining rs2956540 and rs3735520.<sup>28</sup>

Among all SNP variants located in *LOX*, rs2956540 and rs10519694 are 2 intronic variants located in the fourth intron of *LOX*. According to the Genotype-Tissue Expression (GTEx) database (<https://gtexportal.org/home/>), rs2956540 and rs10519694 have been known as expression quantitative trait loci in several tissues. Therefore, it is possible that rs2956540 and rs10519694 might be expression quantitative trait loci in corneal tissue, too, and alter the risk of KC. Also, SNP rs2956540 may affect gene expression through transcriptional regulation, as predicted by Genomatrix (<http://www.genomatix.de/>) that it can alter the binding sites of several transcription factors like PTX1, CMYB, and ISM1.<sup>29</sup>

Few studies have evaluated the association of these 2 variants with KC among different populations.<sup>29</sup> The latest meta-analysis in 2015 showed that rs2956540 and rs10519694 variants have a significant association with KC, whereas it failed to replicate this result in rs1800449 and rs2288393.<sup>29</sup> This study explores the association of rs10519694 and rs2956540 with KC in a population of Iranian descent.

## Methods

The study was performed in Negah Eye Hospital, Tehran, Iran, between January 2020 and January 2022. It was approved by the institutional review board and ethics committee of the Ophthalmic

Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran (IR.SBMU.ORC.REC.1399.015), and met the Declaration of

Table 2. The Clinically Suggested Cutoff Values for Keratoconus Indices in Screening Clinical and Subclinical Cases

Parameter	Clinical Keratoconus	Subclinical Keratoconus
Tomographic		
CKI	*	*
KI	1.07	*
IHA	10.4	*
IHD	0.017	*
TKC	1.0	2.0
ISV	36.6	*
IVA	0.28	0.15
Rmin	7.04	*
PE	20.5	10.5
IS value	1.1	1.9
KISA	60%	100%
Pachymetric		
ART-Min	606	*
ART-Max	356	368
ART-Avg	444	490
BAD_D	2.02	1.31
CCT	515	518
PPI-Min	0.87	0.80
PPI-Max	1.53	1.40
PPI-Avg	1.18	1.08
TCT	506	502

\* = although several studies have addressed the values of these parameters, clear cutoffs have not been achieved; ART = Ambrosio's relational thickness indices; BAD\_D = Belin/Ambrósio deviation; CCT = central corneal thickness; CKI = central keratoconus index; IHA = index of height asymmetry; IHD = index of highest decentration; IS value = the inferior–superior value; ISV = index surface variance; IVA = index of vertical asymmetry; KI = keratoconus index; KISA = The KISA index was derived from the following 4 indices: central K; I-S; the SRAX index, an expression of irregular astigmatism occurring in keratoconus; and the astigmatism index, which quantifies the degree of the regular corneal astigmatism (simulated K1 – simulated K2); PE = prediction error; PPI = pachymetric progression indices; Rmin = minimum radius of curvature; TCT = thinnest corneal thickness; TKC = topographic keratoconus classification.

Table 3. T-ARMS-PCR Primer Sequences, Melting Temperatures ( $T_m$ ), and the Size of PCR Product for Every Genotype

SNP	Primer Sequence	PCR Product	Genotype (Blood Pressure)
rs2956540	Forward inner primer (C allele): ACTTATTTCCTCCATTGCTAAGCC	209	CC (417, 209)
	Reverse inner primer (G allele): GTTTATGCTGAAAATAGAATAGTGGTAGC	265	GG (417, 265)
	Forward outer primer (5' - 3'): CTGACATAGATTTAACTGACACGCATT	417	CG (417, 265, 209)
	Reverse outer primer (5' - 3'): CAGTCCACAAATGAAGAACAAAAATTAC		
rs10519694	Forward inner primer (C allele): AAATATTCACATCAATAAGTAAATGAAGGC	252	CC (402, 252)
	Reverse inner primer (T allele): TATTTTCTCCTCCCAGCCTGTAGACGA	208	TT (402, 208)
	Forward outer primer (5' - 3'): TGTTTGAGTTAGGTAATCAAGGTCC	402	CT (402, 252, 208)
	Reverse outer primer (5' - 3'): TGCTAGAATTGAATGGCAGTATTGAGTT		

SNP = single nucleotide polymorphism; PCR = polymerase chain reaction; T-ARMS = tetra-primer amplification refractory mutation system.

Helsinki criteria. Keratoconus was primarily diagnosed based on clinical criteria including Vogt's striae, Fleischer's ring, corneal stromal thinning and protrusion, and videokeratography findings.<sup>30-32</sup> The Pentacam HR (Oculus) and the Corvis ST (OCULUS Optikgeräte GmbH) were done for all suspicious cases to detect mild forms of KC (Tables 1 and 2).<sup>33-36</sup> All diagnoses were approved by 2 cornea specialists (F.D., A.B.-R.). Complete medical histories were obtained from all patients with KC. No other ocular disorders or risk factors (including contact lens use, eye rubbing, atopy, etc.) or systematic diseases (including connective tissue disorders) were uncovered. All healthy controls had no personal or familial history of eye-related, metabolic, or immune system-related disease. All participants or their legal guardians signed consent forms.

## Genotyping

Five milliliters of peripheral blood was collected from all participants and stored in an ethylenediaminetetraacetic acid (EDTA) tube at  $-20^{\circ}\text{C}$  until DNA was extracted. Total genomic DNA was extracted using a salting-out protocol.<sup>37</sup> Agarose 1% gel electrophoresis and ultraviolet (UV) spectroscopy were used to assess the quality and quantity of extracted DNA, respectively. rs2956540 and rs10519694 were genotyped using tetra-primer amplification refractory mutation system—polymerase chain reaction (PCR). The 3'allele-specific primers designed by the Primer1 online tool (<http://primer1.soton.ac.uk/primer1.html>)

were used for amplification. The tetra-primer amplification refractory mutation system—PCR was carried out in 20  $\mu\text{l}$  mixtures containing 100 ng of genomic DNA, 10  $\mu\text{l}$  of Taq DNA Pol 2X Master Mix Red (Amplicon), 0.5  $\mu\text{l}$  of 2 outer primers, and 1  $\mu\text{l}$  of 2 inner primers for each SNP, and the remainder came from double-distilled water. Polymerase chain reactions were performed using the Eppendorf thermocyclers (Eppendorf AG 22331 OMIM 148300) under the following conditions:  $94^{\circ}\text{C}$  for 4 min, followed by 35 cycles including denaturing at  $94^{\circ}\text{C}$  for 30 s; annealing for 30 s at  $60^{\circ}\text{C}$  and  $62^{\circ}\text{C}$  for rs2956540 and rs10519694, respectively; and extension at  $72^{\circ}\text{C}$  for 30 s. A final extension was conducted at  $72^{\circ}\text{C}$  for 5 min. Finally, the PCR product ran on 2% gel electrophoresis. Based on the sizes of the PCR products on the gel electrophoresis, the genotypes were determined (Table 3).

## Statistical Analysis

All statistical analyses were performed using SPSS Statistics for Windows, version 22.0 (SPSS Inc). Two-tailed Mann–Whitney and Pearson chi-square tests were used to compare age and gender. A Pearson chi-square test was used to compare allele and genotype frequency between cases and controls and to assess divergence from Hardy–Weinberg equilibrium (HWE). The allele risk was evaluated using a 2-tailed Fisher exact test and odds ratio with a 95% confidence interval. Logistic regression was used to fit the general linear model to the data to predict KC risk using

Table 6. rs2956540 and rs10519694 Allele Frequency

	rs2956540		rs10519694	
	C	G	C	T
Case	174 (48%)	182 (52%)	210 (58%)	146 (42%)
Control	160 (44%)	200 (56%)	236 (65%)	124 (35%)
Pearson chi-square	1.2402		3.0124	
df	1		1	
P value	0.2654		0.0826	

C = cytosine; df = degrees of freedom; G = guanine; T = thymine.

Table 7. rs2956540 and rs10519694 Genotype Frequency

	rs2956540			rs10519694		
	CC	CG	GG	CC	TC	TT
Case	34	106	38	54	102	22
Control	39	82	59	84	68	28
Pearson chi-square	7.94			14.03		
df	2			2		
P value <sub>chi-square</sub>	0.019			0.001		

C = cytosine; G = guanine; T = thymine.

Table 8. Comparison of C Allele Carriers of rs2956540 and T Allele Carriers of rs10519694 between Cases and Controls

	rs2956540		rs10519694		
	CC + CG	GG	CC	TT + TC	
Case	140	38	54	124	
Control	121	59	84	96	
Pearson chi-square	5.91		10.08		
df	1		1		
P value <sub>chi-square</sub>	0.015		0.002		
P value <sub>Fisher exact</sub>	0.017		0.001		
OR (CI = 0.95)	1.79		2.01		

CI = confidence interval; C = cytosine; G = guanine; OR = odds ratio; T = thymine.

rs2956540 and rs10519694. Statistical significance was defined as a *P* value of 0.05.

## Results

### Demographic Data

A total of 358 unrelated individuals (178 KC and 180 healthy controls) were enrolled in the study. The mean age of KC patients (92 men and 86 women) and healthy controls (97 men and 83 women) were  $31.97 \pm 9.37$  years and  $32.71 \pm 6.88$  years, respectively (*P* value = 0.33). Gender was matched in both groups (*P* = 0.75) (Table S4).

### HWE

In association studies, we typically hypothesize that healthy controls remain in HWE, whereas the subject groups deviate from HWE. This means one of the frequencies of the genotypes is higher or lower than what would be expected from mutation, natural selection, and so on. Thus, in both rs2956540 and rs10519694, KC subjects departed from HWE (rs2956540: *P* value = 0.038/rs10519694: *P* value = 0.048), whereas healthy controls remained in HWE (rs2956540: *P* value = 0.93/rs10519694: *P* value = 0.090) (Table S5).

Table 9. Gender-Specific Genotype Stratification

		rs2956540			rs10519694			
		CC	CG	GG	CC	TC	TT	
Case	Female	17	53	16	22	49	15	
	Male	17	53	22	32	53	7	
Pearson chi-square		0.746			4.721			
df		2			2			
P value		0.689			0.094			
Control	Female	19	37	27	42	31	10	
	Male	20	45	32	42	37	18	
Pearson chi-square		0.142			1.737			
df		2			2			
P value		0.932			0.420			

C = cytosine; G = guanine; T = thymine.

Table 10. Fitting Logistic Regression Model to Genotype Data

	Beta	Standard Error	P Value	OR
rs2956540	-0.265	0.269	0.323	0.767
rs10519694	-0.725	0.223	0.001	0.484
Intercept	0.670	0.290	0.021	1.954

OR = odds ratio.

### Allele Frequency

To calculate the frequency of each allele, the homozygotes of that allele were multiplied by 2 and added to the heterozygotes, and the result was divided by twice the population of the group. In this set of data, both rs2956540 and rs10519694 risk alleles showed higher frequencies than those displayed in the dbSNP database (rs2956540 C allele = 0.3, rs10519694 T allele = 0.2). Allele frequency did not significantly differ for rs2956540 (*P* value = 0.2654) and rs10519694 (*P* value = 0.08263) between cases and controls (Table 6).

### Genotype Frequency

To calculate the genotype frequency in each group, the total number of each genotype was divided by the total population of that group. Genotype frequency was significantly different between cases and controls for rs2956540 (*P* value = 0.019). rs2956540 C allele carriers (CC and CG) were significantly more frequent among KC cases than healthy controls (*P* value<sub>chi-square</sub> = 0.015, *P* value<sub>Fisher exact</sub> = 0.017). There was a significant difference in genotype frequency between groups for rs10519694 (*P* value = 0.001). T allele carriers were significantly more frequent among KC patients (*P* value<sub>chi-square</sub> = 0.002, *P* value<sub>Fisher exact</sub> = 0.001) (Tables 7 and 8). Sex stratification revealed no significant differences in genotype frequency between men and women in cases and controls (Table 9). Fitting the general linear model showed that rs10519694 could be considered a predictor for the development of KC (*P* value = 0.001); however, this was not observed for rs2956540 (*P* value = 0.323; Table 10).

### Discussion

Keratoconus is a complex, multifactorial, genetic condition that can manifest in isolation or in association with other systemic genetic disorders. Bilaterality, familial aggregation,<sup>38-40</sup> concordant monozygotic twins,<sup>41</sup> correlation with inflammatory bowel disease, Down syndrome,<sup>42</sup> Leber congenital amaurosis,<sup>43</sup> diabetes mellitus,<sup>26</sup> and ethnic<sup>44</sup> differences in prevalence and incidence<sup>45</sup> all point to a genetic cause. Genetic relationships in KC will facilitate discovering biomarkers for early detection and monitoring progression. A total of 14% of KC patients have a family history.<sup>40</sup> It remains uncertain how familial and sporadic KC differ genetically. Because family history does not alter genetic severity, genetic research can pool all cases.<sup>46</sup> Numerous studies have investigated associations between

isolated KC and genetic factors.<sup>2,46-49</sup> Several have suggested *LOX* to be one of the most promising genes associated with KC.<sup>23</sup> Using an oxidative deamination catalytic reaction, *LOX* affects ECM homeostasis and maintenance in collagen and elastin-rich tissues, such as the cornea.<sup>50</sup>

Thus far, numerous studies have examined the association of KC with a wide spectrum of *LOX* single nucleotide variants. Thr392Pro and Pro32Leu substitutions are examples of exonic, nonsynonymous point mutations observed in 2 Brazilian and Chinese KC patients,<sup>8,51</sup> whereas –116C > T and –58C > T are 2 *LOX* 5'UTR mutations that have been observed in 2 advanced KC patients.<sup>51</sup> rs1800449 and rs2288393 are 2 well-known intergenic SNPs whose relationships to KC have been studied extensively.<sup>15,21,52,53</sup> The rs2956540 and rs10519694 are 2 well-known SNPs found in the fourth intron of the *LOX* gene and connected to KC in different populations.<sup>8,12,29,54</sup>

Alterations in *LOX* corneal tissue expression in KC patients have been demonstrated. One study showed *LOX* to be significantly downregulated in KC patients compared with controls.<sup>55</sup> Dudakova et al observed lower *LOX* activity in corneal fibroblast cultures from KC individuals.<sup>14</sup>

In addition to a significant drop in *LOX* mRNA levels, Pahuja et al showed a reduction in the ratio of *LOX* expression with increasing KC grades.<sup>56</sup> Collectively, the results of these studies suggest that alterations in *LOX* biological activity through changes in DNA sequences, particularly in noncoding intronic sequences, correlate with the risk of KC development.

We looked at the relationship between 2 known intronic SNPs in the *LOX* gene, rs2956540 and rs10519694, and KC in a population of Iranian descent. A recent study identified

rs2956540-G as a risk allele for KC in a population of Europeans.<sup>28</sup> However, we found the rs2956540-C allele was highly prevalent in KC patients, whereas the G-allele was more common in the healthy population. Additionally, we noted no significant difference in rs10519694 allele frequency between cases and controls. Furthermore, we found that being an rs10519694-T carrier was more frequently and significantly observed among Iranian KC patients. Although previous studies did not clearly define which rs10519694 allele is the risk allele, we found rs10519694-T to be a significant risk factor for KC. As in previous studies, we found no significant association between gender and rs2956540 and rs10519694 alleles in both KC subjects and healthy controls.

In this study, we examined gene and allele frequencies in a referral center in a consecutive, nonrandom group of Iranian descent. Further studies on KC patients evaluating more SNPs with larger sample sizes in different populations are needed for definitive results.

## Conclusion

We evaluated the association between 2 well-known *LOX* gene SNPs, rs2956540 and rs10519694, and KC in a population of Iranian descent for the first time. We found the rs10519694 variant is more prevalent in KC patients. Further studies should be conducted integrating other genetic information and questionnaires to assess environmental factors and characterize the severity of allergies and frequency of eye rubbing.

## Footnotes and Disclosures

Originally received: August 28, 2022.

Final revision: October 31, 2022.

Accepted: November 3, 2022.

Available online: November 9, 2022.

<sup>1</sup> Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

<sup>2</sup> John A. Moran Eye Center, University of Utah, Salt Lake City, Utah.

<sup>3</sup> Department of Genomic Psychiatry and Behavioral Genomics (DGPBG), Roozbeh Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

<sup>4</sup> Translational Ophthalmology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

<sup>5</sup> Negah Specialty Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

<sup>6</sup> Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

<sup>7</sup> Department of Ophthalmology, Morsani College of Medicine, University of South Florida, Tampa, Florida.

<sup>8</sup> Clinical Research Development Center, Shahid Modarres Educational hospital, Shahid Behesht University of Medical Sciences, Tehran, Iran.

<sup>9</sup> Department of Ophthalmology, Federal University the State of Rio de Janeiro (UNIRIO), São Paulo, Brazil.

<sup>10</sup> Department of Ophthalmology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.

<sup>11</sup> Instituto de Olhos Renato Ambrósio, Rio de Janeiro, Brazil.

<sup>12</sup> Rio de Janeiro Corneal Tomography and Biomechanics Study Group, Rio de Janeiro, Brazil.

<sup>13</sup> BrAIN: Brazilian Artificial Intelligence Networking in Medicine, Rio de Janeiro & Maceió, Brazil.

HUMAN SUBJECTS: The study was approved by the institutional review board and ethics committee of the Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran (IR.SBMU.ORC.REC.1399.015), and met the Declaration of Helsinki criteria.

Obtained funding: N/A.

Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

Disclosure(s):

All authors have completed and submitted the ICMJE disclosures form. The authors made the following disclosures: R.A.: Grant — Oculus Consultant; Consultant — Oculus Consultant.

Author Contributions:

Research design: Sana Niazi, Fatemeh Alizadeh, Farideh Doroodgar, Feizollah Niazi, Renato Ambrósio Jr

Data acquisition and/or research execution: Sana Niazi, Majid Moshirfar, Fatemeh Alizadeh, Farideh Doroodgar

Data analysis and/or interpretation: Sana Niazi, Fatemeh Alizadeh, Farideh Doroodgar

Manuscript preparation: Sana Niazi, Majid Moshirfar, Fatemeh Alizadeh, Farideh Doroodgar, Alireza Baradaran-Rafii, Oliver Filutowski, Feizollah Niazi, Renato Ambrósio Jr

Patient registration: Office Staff of Farideh Doroodgar

Blood sampling and lab exams: Laboratory Team of Negah Hospital

Material preparations: Fatemeh Alizadeh, Feizollah Niazi

#### Abbreviations and Acronyms:

**ECM** = extracellular matrix; **HWE** = Hardy–Weinberg equilibrium; **KC** = keratoconus; **LOX** = lysyl oxidase; **PCR** = polymerase chain reaction; **SNP** = Single nucleotide polymorphism.

#### Keywords:

Cornea, Keratoconus, Extracellular matrix proteins, Genes.

#### Correspondence:

Farideh Doroodgar, MD; Address: Negah Specialty Ophthalmic Hospital and Research Center, No 3., Ketabi St., Shariati Ave., Tehran, Iran; Postal Code: 1544914599 E-mail: [f-doroodgar@farabi.tums.ac.ir](mailto:f-doroodgar@farabi.tums.ac.ir).

## References

1. Davidson A, Hayes S, Hardcastle A, Tuft S. The pathogenesis of keratoconus. *Eye*. 2014;28:189–195.
2. Gordon-Shaag A, Millodot M, Shneor E, Liu Y. The genetic and environmental factors for keratoconus. *Biomed Res Int*. 2015;2015:795738.
3. Buzard KA, Fundingsland BR. Corneal transplant for keratoconus: results in early and late disease. *J Cataract Refract Surg*. 1997;23:398–406.
4. Özalp O, Atalay E, Yıldırım N. Prevalence and risk factors for keratoconus in a university-based population in Turkey. *J Cataract Refract Surg*. 2021;47:1524–1529.
5. Netto EAT, Al-Otaibi WM, Hafezi NL, et al. Prevalence of keratoconus in paediatric patients in Riyadh, Saudi Arabia. *Br J Ophthalmol*. 2018;102:1436–1441.
6. Godefrooij DA, De Wit GA, Uiterwaal CS, et al. Age-specific incidence and prevalence of keratoconus: a nationwide registration study. *Am J Ophthalmol*. 2017;175:169–172.
7. Omer K. Epidemiology of keratoconus worldwide. *Open Ophthalmol J*. 2018;12:289–299.
8. Xu X, Zhang X, Cui Y, et al. Three novel variants identified within ECM-related genes in Chinese Han keratoconus patients. *Scientific Rep*. 2020;10:1–8.
9. Hashemi H, Heydarian S, Hooshmand E, et al. The prevalence and risk factors for keratoconus: a systematic review and meta-analysis. *Cornea*. 2020;39:263–270.
10. Khawaja AP, Rojas Lopez KE, Hardcastle AJ, et al. Genetic variants associated with corneal biomechanical properties and potentially conferring susceptibility to keratoconus in a genome-wide association study. *JAMA Ophthalmol*. 2019;137:1005–1012.
11. Guerra G, de Oliveira V, Ferreira I, et al. Subclinical keratoconus detection in identical twins. *Int J Keratoconus Ectatic Corneal Dis*. 2016;5:35–39.
12. Bykhovskaya Y, Rabinowitz YS. Update on the genetics of keratoconus. *Exp Eye Res*. 2021;202:108398.
13. Khaled ML, Helwa I, Drewry M, et al. Molecular and Histopathological changes associated with keratoconus. *Biomed Res Int*. 2017;2017:7803029.
14. Dudakova L, Liskova P, Trojek T, et al. Changes in lysyl oxidase (LOX) distribution and its decreased activity in keratoconus corneas. *Exp Eye Res*. 2012;104:74–81.
15. Bykhovskaya Y, Li X, Epifantseva I, et al. Variation in the lysyl oxidase (LOX) gene is associated with keratoconus in family-based and case-control studies. *Invest Ophthalmol Vis Sci*. 2012;53:4152–4157.
16. Bykhovskaya Y, Gromova A, Makarenkova HP, Rabinowitz YS. Abnormal regulation of extracellular matrix and adhesion molecules in corneas of patients with keratoconus. *Int J Keratoconus Ectatic Corneal Dis*. 2016;5:63.
17. Collier SA. Is the corneal degradation in keratoconus caused by matrix-metalloproteinases? *Clin Exp Ophthalmol*. 2001;29:340–344.
18. Rabinowitz YS, Dong L, Wistow G. Gene expression profile studies of human keratoconus cornea for NEIBank: a novel cornea-expressed gene and the absence of transcripts for aquaporin 5. *Invest Ophthalmol Vis Sci*. 2005;46:1239–1246.
19. Tai TYT, Damani MR, Vo R, et al. Keratoconus associated with corneal stromal amyloid deposition containing TGFBIP. *Cornea*. 2009;28:589.
20. Macé M, Galiacy SD, Erraud A, et al. Comparative transcriptome and network biology analyses demonstrate anti-proliferative and hyperapoptotic phenotypes in human keratoconus corneas. *Invest Ophthalmol Vis Sci*. 2011;52:6181–6191.
21. Hasanian-Langroudi F, Saravani R, Validad M-H, et al. Association of Lysyl oxidase (LOX) polymorphisms with the risk of Keratoconus in an Iranian population. *Ophthalmic Genet*. 2015;36:309–314.
22. Shetty R, Sathyaranayananmoorthy A, Ramachandra RA, et al. Attenuation of lysyl oxidase and collagen gene expression in keratoconus patient corneal epithelium corresponds to disease severity. *Mol Vis*. 2015;21:12.
23. Bykhovskaya Y, Margines B, Rabinowitz YS. Genetics in Keratoconus: where are we? *Eye Vis*. 2016;3:1–10.
24. Li X, Rabinowitz YS, Tang YG, et al. Two-stage genome-wide linkage scan in keratoconus sib pair families. *Invest Ophthalmol Vis Sci*. 2006;47:3791–3795.
25. Liskova P, Dudakova L, Krepelova A, et al. Replication of SNP associations with keratoconus in a Czech cohort. *PLoS One*. 2017;12(2):e0172365.
26. Ates KM, Estes AJ, Liu Y. Potential underlying genetic associations between keratoconus and diabetes mellitus. *Adv Ophthalmol Pract Res*. 2021;1:100005.
27. Abu-Amero KK, Helwa I, Al-Muammar A, et al. Case-control association between CCT-associated variants and keratoconus in a Saudi Arabian population. *J Negative Results Biomed*. 2015;14:10.
28. Dudakova L, Palos M, Jirsova K, et al. Validation of rs2956540:G>C and rs3735520:G>A association with keratoconus in a population of European descent. *Eur J Hum Genet*. 2015;23:1581–1583.
29. Zhang J, Zhang L, Hong J, et al. Association of common variants in LOX with keratoconus: a meta-analysis. *PLoS One*. 2015;10:e0145815.

30. Rabinowitz YS. Keratoconus. *Surv Ophthalmol*. 1998;42:297–319.
31. Matalia H, Swarup R. Imaging modalities in keratoconus. *Indian J Ophthalmol*. 2013;61:394–400.
32. Kriszt Á, Losonczy G, Berta A, Takács L. Presence of Fleischer ring and prominent corneal nerves in keratoconus relatives and normal controls. *Int J Ophthalmol*. 2015;8:922–927.
33. Ambrósio R, Lopes BT, Faria-Correia F, et al. Integration of Scheimpflug-based corneal Tomography and biomechanical Assessments for Enhancing Ectasia detection. *J Refract Surg*. 2017;33:434–443.
34. Mohammadpour M. *Diagnostics in Ocular Imaging: Cornea, Retina, Glaucoma and Orbit*. Switzerland: Springer Nature; 2020: <https://doi.org/10.1007/978-3-030-54863-6>.
35. Augustin VA, Son H-S, Baur I, et al. Detecting subclinical keratoconus by biomechanical analysis in tomographically regular keratoconus fellow eyes. *Eur J Ophthalmol*. 2022;32:815–822.
36. Kataria P, Padmanabhan P, Gopalakrishnan A, et al. Accuracy of Scheimpflug-derived corneal biomechanical and tomographic indices for detecting subclinical and mild keratectasia in a South Asian population. *J Cataract Refract Surg*. 2019;45:328–336.
37. Chacon Cortes DF, Griffiths L. Methods for extracting genomic DNA from whole blood samples: current perspectives. *J Biorepository Sci Appl Med*. 2014;2014:1–9.
38. Karimian F, Aramesh S, Rabei HM, et al. Topographic evaluation of relatives of patients with keratoconus. *Cornea*. 2008;27:874–878.
39. Kaya V, Utine CA, Altunsoy M, Oral D, et al. Evaluation of corneal topography with Orbscan II in first-degree relatives of patients with keratoconus. *Cornea*. 2008;27:531–534.
40. Zadnik K, Barr JT, Edrington TB, et al. Baseline findings in the collaborative longitudinal evaluation of keratoconus (CLEK) study. *Invest Ophthalmol Vis Sci*. 1998;39:2537–2546.
41. Bechara SJ, Waring 3rd G, Insler MS. Keratoconus in two pairs of identical twins. *Cornea*. 1996;15:90–93.
42. Cullen J, Butler H. Mongolism (Down's syndrome) and keratoconus. *Br J Ophthalmol*. 1963;47:321.
43. Elder MJ. Leber congenital amaurosis and its association with keratoconus and keratoglobus. *J Pediatr Ophthalmol Strabismus*. 1994;31:38–40.
44. Hardcastle AJ, Liskova P, Bykhovskaya Y, et al. A multi-ethnic genome-wide association study implicates collagen matrix integrity and cell differentiation pathways in keratoconus. *Commun Biol*. 2021;4:1–13.
45. Georgiou T, Funnell C, Cassels-Brown A, O'conor R. Influence of ethnic origin on the incidence of keratoconus and associated atopic disease in Asians and white patients. *Eye*. 2004;18:379–383.
46. Rong SS, Ma STU, Yu XT, et al. Genetic associations for keratoconus: a systematic review and meta-analysis. *Scientific Rep*. 2017;7:1–11. [https://doi.org/10.1007/978-981-16-4247-0\\_3](https://doi.org/10.1007/978-981-16-4247-0_3).
47. Wang Y, Rabinowitz Y, Rotter J, Yang H. Genetic epidemiological study of keratoconus: evidence for major gene determination. *Am J Med Genet*. 2000;93:403–409.
48. Kalra N Sinha R. Genetics of keratoconus. In: Nema HV, Nema N, eds. *Genetics of Ocular Diseases*. Springer Nature Singapore; 2022:15–23.
49. Hutchings H, Ginisty H, Le Gallo M, et al. Identification of a new locus for isolated familial keratoconus at 2p24. *J Med Genet*. 2005;42:88.
50. Cai L, Xiong X, Kong X, Xie J. The role of the lysyl oxidases in tissue repair and remodeling: a concise review. *Tissue Eng Regen Med*. 2017;14:15–30.
51. Gadelha DNB, Feitosa AFB, da Silva RG, et al. Screening for novel LOX and SOD1 variants in keratoconus patients from Brazil. *J Ophthalmic Vis Res*. 2020;15:138.
52. Xiao W, He J, Fu W, Xu Y, Zhang Z. LOX gene polymorphisms are associated with osteoporotic vertebral compression fracture in postmenopausal Chinese women. *Gene*. 2020;741:144543.
53. Siddique PM, Malik RK, Chohan AA, et al. *Analysis of VSXI, HGF and LOX in the Pakistani familial and sporadic Keratoconus patients*. New York Scientific Data Summit (NYSDS); 2016:1. <https://doi.org/10.1109/NYSDS.2016.7747822>.
54. Mok J-W, So H-R, Ha M-J, Na K-S, Joo C-K. Association with corneal remodeling related genes, ALDH3A1, LOX, and SPARC genes Variations in Korean keratoconus patients. *Korean J Ophthalmol*. 2021;35:120.
55. Karolak JA, Ginter-Matuszewska B, Tomela K, et al. Further evaluation of differential expression of keratoconus candidate genes in human corneas. *PeerJ*. 2020;8:e9793.
56. Pahuja N, Kumar NR, Shroff R, et al. Differential molecular expression of extracellular matrix and inflammatory genes at the corneal cone apex drives focal weakening in keratoconus. *Invest Ophthalmol Vis Sci*. 2016;57:5372–5382.